Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 5, 2006, Pages 639-645

  Wade, Derick T ^a   Makela, P M ^a   House, H ^a   Bateman, C ^a   Robson, P ^b  

^a OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

^b WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Cannabis; Chronic use; Multiple sclerosis; Safety

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABIS; ANALGESIC AGENT; CANNABINOID; PLANT MEDICINAL PRODUCT;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; ATTENTION DISTURBANCE; BALANCE DISORDER; BREAST CANCER; CANNABIS INTOXICATION; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DECUBITUS; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INTOXICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; FALLING; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HOT FLUSH; HUMAN; INFORMED CONSENT; INTERRUPTED SLEEP; LETHARGY; LIVER FUNCTION TEST; LONG TERM CARE; LOOSE FECES; LUNG CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MOOD CHANGE; MOUTH PAIN; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; ORAL MUCOSAL DISEASE; OSTEOMYELITIS; PATIENT ASSESSMENT; PLEURISY; PNEUMONIA; PRIMARY BILIARY CIRRHOSIS; RELAPSE; SCORING SYSTEM; SEIZURE; SEPSIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPASTICITY; TASTE DISORDER; TOOTH DISCOLORATION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; VIVID DREAM; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; EVALUATION; MIDDLE AGED; PAIN ASSESSMENT; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; CANNABINOIDS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN MEASUREMENT; PHYTOTHERAPY; PLANT PREPARATIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745025055     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458505070618     Document Type: Article

References (16)

1. Ungerleider T, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
2. Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-THC. J Clin Pharmacol 1981; 21: 413S-16S.
3. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
4. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
5. Wade DT, Robson PJ, House H, Makela PM, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
6. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A on behalf of the UK MS research group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
7. Wade DT, Makela P, Robson PJ, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomised, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
8. Vaney C, Heinzel-Guttenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomised, double-blind, placebo-controlled crossover study. Mult Scler 2004; 10: 417-24.
9. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004; 10: 425-33.
10. Svendsen KB, Jensen TS, Back FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised, double-blind, placebo-controlled crossover trial. Br Med J 2004; 329: 253-x.
11. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-31.
12. Arseneault L, Cannon M, Witton J Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-17.
13. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-22.
14. McPartland J, Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therapeut 2001; 1: 103-32.
15. Collin C, Wade DT, Davis S, Home V. The Barthel ADL Index: a reliability study. Int Disabil Stud 1988; 10: 61-63.
16. Rossier P, Wade DT. The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity. Clin Rehabil 2002; 16: 75-95.